Related references
Note: Only part of the references are listed.Three dimensions of the amyloid hypothesis: time, space and 'wingmen'
Erik S. Musiek et al.
NATURE NEUROSCIENCE (2015)
Lessons from a BACE1 inhibitor trial: Off-site but not off base
Debomoy K. Lahiri et al.
ALZHEIMERS & DEMENTIA (2014)
BACE1 (beta-secretase) inhibitors for the treatment of Alzheimer's disease
Arun K. Ghosh et al.
CHEMICAL SOCIETY REVIEWS (2014)
Models of β-amyloid induced Tau-pathology: the long and folded road to understand the mechanism
Ilie-Cosmin Stancu et al.
MOLECULAR NEURODEGENERATION (2014)
AZD3293 A NOVEL BACE1 INHIBITOR: SAFETY, TOLERABILITY, AND EFFECTS ON PLASMA AND CSF Aβ PEPTIDES FOLLOWING SINGLE- AND MULTIPLE-DOSE ADMINISTRATION
Robert Alexander et al.
NEUROBIOLOGY OF AGING (2014)
BACE1 inhibitor drugs in clinical trials for Alzheimer's disease
Robert Vassar
ALZHEIMERS RESEARCH & THERAPY (2014)
β-secretase inhibitor; a promising novel therapeutic drug in Alzheimer's disease
Kelly Willemijn Menting et al.
FRONTIERS IN AGING NEUROSCIENCE (2014)
The novel BACE inhibitor MK-8931 dramatically lowers CSF beta-amyloid in patients with mild-to-moderate Alzheimer's disease
Mark Forman et al.
Alzheimers & Dementia (2013)
Clinical study of E2609, a novel BACE1 inhibitor, demonstrates target engagement and inhibition of BACE1 activity in CSF
Francois Bernier et al.
Alzheimers & Dementia (2013)
Structure-Based Design of β-Site APP Cleaving Enzyme 1 (BACE1) Inhibitors for the Treatment of Alzheimer's Disease
Jing Yuan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
The novel BACE inhibitor MK-8931 dramatically lowers cerebrospinal fluid Aβ peptides in healthy subjects following single- and multiple-dose administration
Mark Forman et al.
Alzheimers & Dementia (2012)
BACE inhibitor LY2886721 safety and central and peripheral PK and PD in healthy subjects (HSs)
Ferenc Martenyi et al.
Alzheimers & Dementia (2012)
Developing ß-secretase inhibitors for treatment of Alzheimer's disease
Arun K. Ghosh et al.
JOURNAL OF NEUROCHEMISTRY (2012)
β-Secretase inhibitor GRL-8234 rescues age-related cognitive decline in APP transgenic mice
Wan-Pin Chang et al.
FASEB JOURNAL (2011)
Robust Central Reduction of Amyloid-β in Humans with an Orally Available, Non-Peptidic β-Secretase Inhibitor
Patrick C. May et al.
JOURNAL OF NEUROSCIENCE (2011)
BACE1 Deficiency Causes Altered Neuronal Activity and Neurodegeneration
Xiangyou Hu et al.
JOURNAL OF NEUROSCIENCE (2010)
γ-secretase inhibition and modulation for Alzheimer's disease
Michael S. Wolfe
CURRENT ALZHEIMER RESEARCH (2008)
Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP transgenic mice
Lisa McConlogue et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Control of peripheral nerve myelination by the β-secretase BACE1
Michael Willem et al.
SCIENCE (2006)
Alzheimer therapeutics-what after the cholinesterase inhibitors?
Lary C. Walker et al.
AGE AND AGEING (2006)
Cathepsin D deficiency is associated with a human neurodegenerative disorder
Robert Steinfeld et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2006)
BACE1, a major determinant of selective vulnerability of the brain to amyloid-β amyloidogenesis, is essential for cognitive, emotional, and synaptic functions
FM Laird et al.
JOURNAL OF NEUROSCIENCE (2005)
BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease
M Ohno et al.
NEURON (2004)
Specificity of memapsin 1 and its implications on the design of memapsin 2 (β-secretase) inhibitor selectivity
RT Turner et al.
BIOCHEMISTRY (2002)
Subsite specificity of memapsin 2 (β-secretase):: Implications for inhibitor design
RT Turner et al.
BIOCHEMISTRY (2001)
Structure of the protease domain of memapsin 2 (β-secretase) complexed with inhibitor
L Hong et al.
SCIENCE (2000)
Design of potent inhibitors for human brain memapsin 2 (β-secretase)
AK Ghosh et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2000)
Share Paper
